FCF Grants Awarded to Dracen Pharmaceuticals
Total grants: 1
- Exploiting a Critical Vulnerability to Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC) — Principal investigator(s): Marina Baretti, Mark Yarchoan — 2023
This list represents the complete set of Fibrolamellar Cancer Foundation grants awarded to Dracen Pharmaceuticals.